Illumina, Inc.
Illumina, Inc. (Nasdaq: ILMN) develops sequencing- and array-based solutions for genetic and genomic analysis, serving research and clinical customers including universities, government laboratories, hospitals, pharmaceutical and biotechnology companies, molecular diagnostic laboratories, and consumer genomics… From the company’s description.
In fiscal 2025, Illumina, Inc. reported revenue of $4.34B, down 0.7% from fiscal 2024, and net income of $850.00M. Its operating margin was 18.6%, and operations generated $1.08B in cash. Over the twelve months to Jun 28, 2026, revenue was $4.49B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Illumina, Inc. does
In the company’s own words
Illumina, Inc. (Nasdaq: ILMN) develops sequencing- and array-based solutions for genetic and genomic analysis, serving research and clinical customers including universities, government laboratories, hospitals, pharmaceutical and biotechnology companies, molecular diagnostic laboratories, and consumer genomics businesses. Its integrated portfolio includes sequencing and microarray instruments, consumables such as reagents and library-preparation kits, genomic data-analysis software, and customer services. Applications span basic research, drug development, oncology, genetic and reproductive health, consumer genomics, and agricultural research. Sequencing accounted for 92% of revenue in fiscal 2025, with arrays contributing 8%; consumables represented 74% of total revenue. Illumina has one reportable segment, Core Illumina. As of December 28, 2025, its global workforce included approximately 8,600 full-time employees, 50 part-time employees, and 1,430 contingent workers. In 2024, Illumina separated GRAIL into an independent public company. Its website is www.illumina.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- January
- CIK
- 1110803
- SIC
- 3826
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Illumina, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Illumina, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Illumina, Inc.’s bonds, as funds hold them
Funds report holding 4 issues of Illumina, Inc.’s debt, $565.88M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.76%, maturing 2026 to 2031.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Illumina, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Illumina, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Illumina, Inc.'s last four quarterly filings that the numbers alone won't show?”